- Published at
- by manilatimes.net
positive
positive
News for Abeona Therapeutics Inc. (ABEO)
- Published at
- by gurufocus.com
positivepositiveAbeona Therapeutics Inc (ABEO) Q4 2024 Earnings Call Highlights: Strategic Advancements and Financial Resilience
Cash and Cash Equivalents: $98.1 million as of December 31, 2024, compared to $52.6 million as of December 31, 2023.Research and Development Expenses: $34.4 mi- Published at
- by gurufocus.com
positivepositiveQ4 2024 Abeona Therapeutics Inc Earnings Call Transcript
Mar 20, 2025 / 12:30PM GMTOperator Greetings. Welcome to Abeona Therapeutics full year 2024 results and business update conference call. (Operator Instructions)- Published at
- by seekingalpha.com
neutralneutralAbeona Therapeutics Inc. 2024 Q4 - Results - Earnings Call Presentation (NASDAQ:ABEO)
The following slide deck was published by Abeona Therapeutics Inc.- Published at
- by seekingalpha.com
neutralneutralAbeona Therapeutics targets $2B revenue potential for pz-cel amid U.S. launch preparations (NASDAQ:ABEO)
Gain insights into Abeona Therapeutics' Q4 2024 earnings call.- Published at
- by seekingalpha.com
positivepositiveAbeona Therapeutics Inc. (ABEO) Q4 2024 Earnings Call Transcript
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ETCompany ParticipantsGreg Gin – Vice President-Investor...- Published at
- by gurufocus.com
neutralneutralAbeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory Update and Commercial Launch Plans
FDA priority review of pz-cel Biologics License Application (BLA) progressing with Prescription Drug User Fee Act (PDUFA) target action date of April 29, 2025- Published at
- by seekingalpha.com
neutralneutralAbeona Therapeutics GAAP EPS of -$1.55 beats by $0.21 (NASDAQ:ABEO)
Abeona Therapeutics (ABEO) reports improved FY EPS, strong cash position of $98.1M, and sufficient funding into 2026.- Published at
- by benzinga.com
positivepositiveThis Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Abeona Therapeutics (NASDAQ:ABEO), Fluence Energy (NASDAQ:FLNC)
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...- Published at
- by gurufocus.com
neutralneutralAbeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference
CLEVELAND, March 04, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. ( ABEO) today announced that Abeona's Chief Executive Officer, Vish Seshadri, Ph.D., M.- Published at
- by gurufocus.com
positivepositiveAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, March 03, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. ( ABEO) today announced it has granted equity awards to new non-executive employees who- Published at
- by manilatimes.net
positivepositive- Published at
- by gurufocus.com
positivepositive- Published at
- by gurufocus.com
mixedmixedRosalind Advisors, Inc. Increases Stake in OptiNose Inc.
On December 31, 2024, Rosalind Advisors, Inc. (Trades, Portfolio) made a significant move by adding 412,087 shares of OptiNose Inc. (NASDAQ: OPTN) to its portfo- Published at
- by gurufocus.com
positivepositiveRosalind Advisors, Inc. Expands Stake in InspireMD Inc.
On December 31, 2024, Rosalind Advisors, Inc. (Trades, Portfolio) significantly increased its investment in InspireMD Inc. by acquiring an additional 7,419,918- Published at
- by gurufocus.com
positivepositiveAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. ( ABEO) today announced it has granted equity awards to new non-executive employees who- Published at
- by gurufocus.com
positivepositiveInsider Sell: Mark Alvino Sells 4,000 Shares of Abeona Therapeutics Inc (ABEO)
On January 29, 2025, Mark Alvino, a Director at Abeona Therapeutics Inc (ABEO), sold 4,000 shares of the company. Following this transaction, the insider now ow- Published at
- by seekingalpha.com
neutralneutralAbeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued (ABEO)
Abeona Therapeutics Inc.'s promising gene therapy for RDEB, potential FDA approval, undervalued stock, and key risks. Click for our ABEO stock update.- Published at
- by manilatimes.net
positivepositive- Published at
- by gurufocus.com
positivepositiveRosalind Advisors, Inc. Acquires Significant Stake in Neuraxis Inc
On November 12, 2024, Rosalind Advisors, Inc. (Trades, Portfolio) made a strategic move by acquiring 2,100,840 shares of Neuraxis Inc (NRXS). This transaction,